key: cord-1005676-iicomeki
authors: Eslamian, Laleh; Ahmadi, Marjan; Ahmadi, Mahnaz
title: Prescribing Aspirin for Preeclampsia Prevention in Pregnant Women During COVID-19: Should or Shouldn’t?
date: 2021
journal: Iran J Pharm Res
DOI: 10.22037/ijpr.2021.115076.15183
sha: d873b3ad46667bb5dd71c7070fb7da31dd2dfed0
doc_id: 1005676
cord_uid: iicomeki

nan

One of the most common complications during pregnancy is preeclampsia, a multisystemic disorder that results in high blood pressure and multiple organ damage. It usually begins after 20 weeks of gestation. It is estimated that 2-8% of pregnant women experience eclampsia worldwide. Each year more than 287,000 women die due to pregnancy-related diseases, and eclampsia accounts for 10-15% of them (1) . It is suggested that prescribing low-dose aspirin prevents preeclampsia in 60-90% of pregnant women (2) .

COVID-19 pandemic began in December 2019 as an acute respiratory disease with severe morbidities and high mortality rates. Still, we know little about COVID-19 in pregnancy. The studies demonstrate that pregnant women are at higher risk of experiencing more severe disease (3) .

There is concern about aspirin administration, which could have side effects on patients with respiratory illnesses such as COVID-19. The American College of Obstetricians and Gynecologists (ACOG), International Federation of Gynaecology and Obstetrics (FIGO), Society for Maternal-Fetal Medicine (SFMF), and Society of Obstetricians and Gynaecologists of Canada (SOGC) guidelines stated that during the pandemic, low-dose aspirin could be prescribed to pregnant women as clinically indicated. For the patients infected with COVID-19 or at risk of infection, low-dose aspirin could be prescribed, and care modifications may be individualized (4-6). However, the Royal College of Obstetricians and Gynaecologists (RCOG) guideline suggested aspirin for women with thrombocytopenia or platelets lower than 50000/mL should not be prescribed (7) .

Some research suggests no evidence of acute side effects and long-term negative effects or a significant decrease in quality of life in pregnant women infected with COVID-19 taking NSAIDs (8) . Moreover, according to mentioned guidelines, it seems that during the COVID-19 pandemic, it is necessary to screen the pregnant women in the first trimester for preeclampsia and offer low-dose aspirin for the ones who become high-risk.

Maternal prepregnancy overweight and obesity and the risk of preeclampsia: A meta-analysis of cohort studies

Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial

SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes

Society for maternal-fetal medicine management considerations for pregnant patients with COVID-19

Updated SOGC committee opinion -COVID-19 in pregnancy

Coronavirus (COVID-19) infection in pregnancy

Coronavirus disease 19 (Covid-19) and nonsteroidal anti-inflammatory drugs (NSAID)